Ascendis Pharma AS (ASND)
130.01
+7.37
(+6.01%)
USD |
NASDAQ |
Nov 22, 16:00
130.01
0.00 (0.00%)
After-Hours: 17:54
Ascendis Pharma Total Assets (Quarterly): 1.222B for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.222B |
| June 30, 2024 | 812.82M |
| March 31, 2024 | 866.62M |
| December 31, 2023 | 912.60M |
| September 30, 2023 | 924.30M |
| June 30, 2023 | 895.28M |
| March 31, 2023 | 1.054B |
| December 31, 2022 | 1.169B |
| September 30, 2022 | 1.252B |
| June 30, 2022 | 1.386B |
| March 31, 2022 | 1.537B |
| December 31, 2021 | 1.228B |
| September 30, 2021 | 1.398B |
| June 30, 2021 | 1.014B |
| March 31, 2021 | 1.132B |
| December 31, 2020 | 1.205B |
| September 30, 2020 | 1.228B |
| June 30, 2020 | 630.50M |
| March 31, 2020 | 685.37M |
| December 31, 2019 | 758.05M |
| September 30, 2019 | 804.12M |
| Date | Value |
|---|---|
| June 30, 2019 | 872.26M |
| March 31, 2019 | 855.66M |
| December 31, 2018 | 364.87M |
| September 30, 2018 | 389.54M |
| June 30, 2018 | 426.48M |
| March 31, 2018 | 449.79M |
| December 31, 2017 | 253.11M |
| September 30, 2017 | 261.58M |
| June 30, 2017 | 162.90M |
| March 31, 2017 | 184.62M |
| December 31, 2016 | 200.94M |
| September 30, 2016 | 97.33M |
| June 30, 2016 | 114.28M |
| March 31, 2016 | 127.70M |
| December 31, 2015 | 144.07M |
| September 30, 2015 | 158.95M |
| June 30, 2015 | 166.12M |
| March 31, 2015 | 174.66M |
| December 31, 2014 | 71.35M |
| September 30, 2014 | 19.96M |
| December 31, 2013 | 36.87M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
630.50M
Minimum
Jun 2020
1.537B
Maximum
Mar 2022
1.065B
Average
1.093B
Median
Total Assets (Quarterly) Benchmarks
| Novo Nordisk AS | 59.53B |
| Evaxion Biotech AS | 15.18M |
| Trinity Biotech PLC | 97.45M |
| Biodexa Pharmaceuticals PLC | 17.67M |
| NuCana PLC | 25.38M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 1.330B |
| Shareholders Equity (Quarterly) | -108.70M |
| Debt to Equity Ratio | -8.104 |
| Current Ratio | 1.161 |
| Net Debt Paydown Yield | -0.74% |